Shenzhen Salubris Pharmaceuticals Co. Ltd. has discovered dual antagonists of endothelin ETA receptor (EDNRA; ETRA) and angiotensin AT1 receptor (AGTR1; AT1). They are reported to be useful for the treatment of chronic kidney disease, IgA nephropathy, focal segmental glomerulosclerosis and hypertension.

Nanjing Anji Biotechnology Co. Ltd. has discovered 2-oxoglutarate dehydrogenase, mitochondrial (OGDH; OGDC-E1) inhibitors. They are reported to be useful for the treatment of schizophrenia, liver fibrosis, liver cancer, diabetic nephropathy, heart failure, Alzheimer’s, Parkinson’s and Huntington’s disease, among others.

Aurigene Oncology Ltd. has identified compounds acting as E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Ewha Womans University has reported Bruton tyrosine kinase (BTK) inhibitors described as potentially useful for the treatment of autoimmune disease and cancer.

Kymera Therapeutics Inc. has reported signal transducer and activator of transcription 6 (STAT6) inhibitors.

Yuhan Corp. has disclosed triggering receptor expressed on myeloid cells 2 (TREM2) agonists described as potentially useful for the treatment of neurological disorders.

Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of arthritis and psoriasis.

Voronoi Inc. has divulged hepatocyte growth factor receptor (HGFR; c-MET) inhibitors. They are reported to be useful for the treatment of cancer.

Sundance Biosciences Inc. has discovered non-receptor tyrosine-protein kinase TYK2 inhibitors potentially useful for the treatment of multiple sclerosis.

Scientists from Merck Sharp & Dohme LLC and Otsuka Pharmaceutical Co. Ltd. have identified cellular tumor antigen p53 (TP53) Y220C mutant stabilizers reported to be useful for the treatment of cancer.